[go: up one dir, main page]

WO1998008535A3 - Method of causing selective immunosuppression using HL-60-related lectins - Google Patents

Method of causing selective immunosuppression using HL-60-related lectins Download PDF

Info

Publication number
WO1998008535A3
WO1998008535A3 PCT/US1997/015016 US9715016W WO9808535A3 WO 1998008535 A3 WO1998008535 A3 WO 1998008535A3 US 9715016 W US9715016 W US 9715016W WO 9808535 A3 WO9808535 A3 WO 9808535A3
Authority
WO
WIPO (PCT)
Prior art keywords
lectin
treating
causing selective
tumor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/015016
Other languages
French (fr)
Other versions
WO1998008535A2 (en
Inventor
Linda G Baum
Nancy L Perillo
Jeffrey J Seilhamer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD, Incyte Pharmaceuticals Inc filed Critical University of California Berkeley
Priority to AU40913/97A priority Critical patent/AU4091397A/en
Publication of WO1998008535A2 publication Critical patent/WO1998008535A2/en
Publication of WO1998008535A3 publication Critical patent/WO1998008535A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides methods of treating a neoplastic disease characterized by proliferation of lymphocytes by administering pharmaceutical compositions comprising a soluble lectin having a molecular weight of about 14 kilodaltons. In addition, methods of treating a lectin-producing tumor by administering an effective amount of an antibody that specifically binds the lectin, lectin antagonists, inhibitory saccharides, or glycosylation inhibitors in order to prevent lectin-induced apoptosis of tumor-infiltrating T cells.
PCT/US1997/015016 1996-08-26 1997-08-26 Method of causing selective immunosuppression using hl-60-related lectins Ceased WO1998008535A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40913/97A AU4091397A (en) 1996-08-26 1997-08-26 Method of causing selective immunosuppression using hl-60-related lectins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70480296A 1996-08-26 1996-08-26
US08/704,802 1996-08-26

Publications (2)

Publication Number Publication Date
WO1998008535A2 WO1998008535A2 (en) 1998-03-05
WO1998008535A3 true WO1998008535A3 (en) 1998-05-28

Family

ID=24830917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015016 Ceased WO1998008535A2 (en) 1996-08-26 1997-08-26 Method of causing selective immunosuppression using hl-60-related lectins

Country Status (2)

Country Link
AU (1) AU4091397A (en)
WO (1) WO1998008535A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890531B1 (en) 1998-07-31 2005-05-10 Kirin Beer Kabushiki Kaisha Neuronal growth factor galectin-1
TW200617393A (en) * 2004-11-22 2006-06-01 Univ Nat Cheng Kung Method for testing lectin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337799A2 (en) * 1988-04-14 1989-10-18 Incyte Pharmaceuticals, Inc. 14-Beta-gal mammalian lectins
WO1992019239A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Treatment of aberrant cellular states with biomodulators
WO1994011497A1 (en) * 1992-11-16 1994-05-26 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using hl-60-related lectins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0337799A2 (en) * 1988-04-14 1989-10-18 Incyte Pharmaceuticals, Inc. 14-Beta-gal mammalian lectins
WO1992019239A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Treatment of aberrant cellular states with biomodulators
WO1994011497A1 (en) * 1992-11-16 1994-05-26 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using hl-60-related lectins

Also Published As

Publication number Publication date
AU4091397A (en) 1998-03-19
WO1998008535A2 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
BG104245A (en) Plasma protein-containing pharmaceutical compositions
CA2271857A1 (en) Method for treating symptoms of diabetes
CA2162600A1 (en) Compositions Comprising Complement Related Proteins and Carbohydrates, and Methods for Producing and Using Said Compositions
WO2002002638A3 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
CA2146973A1 (en) Uses of tgf-.beta. receptor fragment as a therapeutic agent
DZ2172A1 (en) Triazole derivatives useful in therapy, process for their preparation and compositions containing them.
FR2732967B1 (en) 1-PHENYLPYRAZOLE-3-CARBOXAMIDES SUBSTITUTED, ACTIVE IN NEUROTENSIN, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EP1273304A3 (en) Use of interleukin-15
OA09374A (en) "New 1, 2, 3, 4, 5, 6-hexahydroazepino [4,5-b] indoles and 1, 2, 3, 4-tetrahydro B carbolines, their preparation processes and pharmaceutical compositions which contain them".
CA2278422A1 (en) D-methadone, a nonopioid analgesic
EP0999219A3 (en) Novel heparin binding peptides
IT8904847A0 (en) TRACKED VEHICLE, PARTICULARLY FOR THE PREPARATION OF SKI SLOPES.
ATE325803T1 (en) GLYCOCONJUGATES, GLYCOAMINO ACIDS, THEIR INTERMEDIATE PRODUCTS, AND THEIR USE
WO1998008535A3 (en) Method of causing selective immunosuppression using HL-60-related lectins
ITMI912745A0 (en) 5H-BENZODIAZEPE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PROCEDURE FOR THEIR PREPARATION.
FR2652487B1 (en) PROTECTION AGAINST WEAR FOR SHOES.
CA2066031A1 (en) Methods for reducing non-target retention of immunoconjugates and metabolites thereof
IT8719700A0 (en) 2-THIOMETHYL-SUSTITUTED-PYRIDINES, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
IT8125431A0 (en) DEVICE FOR THE PREPARATION OF GRAIN MATERIAL, IN PARTICULAR FOUNDRY EARTH.
GB2244998B (en) Extracellular expolymer,process for its preparation and pharmaceutical compositions containing the said exopolymer
FR2698799B1 (en) Machine for flattening cereal grains, in particular.
IT8119758A0 (en) 2'-DEOXY-3',5'-DI-O-ALKYLCARBONIL-5-FLUORIDE DINIC DERIVATIVES PROCESS FOR THEIR PREPARATION AND ANTI-CANCER AGENTS WHICH CONTAIN THE SAID DERIVATIVES.
IT1210859B (en) CHEMOTHERAPY COMPOUND, PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS.
KUROKI Performance of Meat Oligopolistic Business Group Focused on full-cost principle
IT8622783A0 (en) IMIDAZOLE DERIVATIVES THERAPEUTIC SUITABILITY, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998511850

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA